Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer

Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer is a phase 2, interventional study registered as NCT07059949 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 80 participants, started 2025-06-30 and due to reach its primary completion in 2027-01-30. Interventions recorded: CAPOX+ Camrelizumab+ Cetuximab; CAPOX+ Camrelizumab+ Bevacizumab. Conditions listed: Unresectable Metastatic Rectal Cancer; CAPOX; Combination of Radioimmunotherapy. Primary outcome: ORR. Colorectal eligibility wording from the registry: "Histologically confirmed rectal cancer with initial treatment (no surgery, radiotherapy, chemotherapy, targeted therapy or immunotherapy);". No results are recorded here; the registry entry is the source.